Eli Lilly and Company $LLY Stock Holdings Cut by Eagle Wealth Strategies LLC

Eagle Wealth Strategies LLC trimmed its position in Eli Lilly and Company (NYSE:LLY) by 0.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,122 shares of the company’s stock after selling 27 shares during the period. Eli Lilly and Company comprises 1.8% of Eagle Wealth Strategies LLC’s portfolio, making the stock its 10th biggest holding. Eagle Wealth Strategies LLC’s holdings in Eli Lilly and Company were worth $3,213,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Duquesne Family Office LLC lifted its position in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock valued at $78,321,000 after buying an additional 32,640 shares in the last quarter. Corient IA LLC purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $570,000. LS Investment Advisors LLC lifted its position in shares of Eli Lilly and Company by 1.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company’s stock valued at $1,933,000 after buying an additional 40 shares in the last quarter. Cutter Capital Management LP purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $14,866,000. Finally, Prism Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the 1st quarter valued at about $207,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of analyst reports. Cantor Fitzgerald lowered their price objective on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 13th. Hsbc Global Res raised Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a research report on Sunday, August 17th. Berenberg Bank reissued a “hold” rating and issued a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $939.61.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $725.54 on Tuesday. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The stock’s 50 day simple moving average is $733.42 and its two-hundred day simple moving average is $765.98. The company has a market cap of $686.69 billion, a price-to-earnings ratio of 47.42, a PEG ratio of 1.01 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insider Activity

In related news, Director J Erik Fyrwald bought 1,565 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares in the company, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the transaction, the director owned 2,703 shares in the company, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have purchased 4,514 shares of company stock worth $2,894,841. Company insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.